Evidence map›Paper›PMID 40991840›Full record

ArticleCancer science2025

GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab.

Tokiyoshi Tanegashima, Masaki Shiota, Shusuke Akamatsu, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Tokiyoshi TanegashimaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-1631-4720
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-3306-4858
Shusuke AkamatsuDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hideaki MiyakeDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Masayuki TakahashiDepartment of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2048-4263
Norihiko TsuchiyaDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Naoya MasumoriDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Hideyasu MatsuyamaDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
Wataru ObaraDepartment of Urology, Iwate Medical University School of Medicine, Iwate, Japan.ORCID https://orcid.org/0000-0003-2720-9640
Nobuo ShinoharaDepartment of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID https://orcid.org/0000-0002-6695-294X
Kiyohide FujimotoDepartment of Urology, Nara Medical University, Kashihara, Japan.ORCID https://orcid.org/0000-0003-1507-2464
Masahiro NozawaDepartment of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
Kojiro OhbaDepartment of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Katsuyoshi HashineDepartment of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
Tomomi KambaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Koji MitaDepartment of Urology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Momokazu GotohDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shuichi TataranoDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Masato FujisawaDepartment of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Yoshihiko TomitaDepartment of Urology and Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
Shoichiro MukaiDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Keiichi ItoDepartment of Urology, National Defense Medical College, Saitama, Japan.ORCID https://orcid.org/0000-0001-8524-2903
Shoji TokunagaMedical Information Center, Kyushu University Hospital, Fukuoka, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-3312-9930
SNiP‐RCC investigators

Funding

Clinical Research Support Center Kyushu from Ono Pharmaceutical and Bristol-Myers Squibb
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced renal cell carcinoma (RCC). However, ICIs often induce immune-related adverse events (irAEs), which vary greatly among individuals and may influence treatment outcomes. This study aimed to identify genetic markers associated with the risk of severe treatment-related adverse events (trAEs) and assess their impact on patient prognosis. From August 19, 2019, to September 30, 2020, patient recruitment for nivolumab treatment in advanced clear cell RCC (ccRCC) was conducted across 23 institutions in Japan, with follow-up concluding on March 31, 2021 (protocol ID: UMIN000037739). A genome-wide association study (GWAS) was conducted in a development cohort to identify single nucleotide polymorphisms (SNPs) associated with severe trAEs following nivolumab. Sixteen SNPs were identified, and thirteen were genotyped in a validation cohort. Eight SNPs showed consistent trends with the development cohort, but they have not reached statistical significance in the validation cohort. Among them, rs2545737, corresponding to CHD1, was significantly linked to prolonged progression-free survival (PFS), highlighting its potential as a biomarker for both safety and efficacy. Further analysis indicated that high CHD1 expression in tumors correlated with improved overall survival in nivolumab-treated patients but not in those receiving everolimus. Given the failure to replicate the development set findings in our validation cohort, further re-validation within the RCC population is warranted. However, these results enhance our understanding of the genetic predisposition to trAEs and provide a significant step toward safer and more effective cancer treatment strategies. This study was registered on the University Hospital Medical Information Network (UMIN) in Japan on August 20, 2019 (protocol ID: UMIN000037739).

Indexed as

Carcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsNivolumabPolymorphism, Single NucleotideAdultAgedAged, 80 and overBiomarkers, TumorFemaleGenome-Wide Association StudyHumansJapanMaleMiddle AgedPrognosisBiomarkers, TumorImmune Checkpoint InhibitorsNivolumabanti‐PD‐1 antibodygenome‐wide association studynivolumabrenal cell carcinomasingle nucleotide polymorphismtreatment‐related adverse event

Identifiers

PMID40991840
PMCPMC12666458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.